I hereby certify that this paper is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EM 021709886 US, on the date shown below in an envelope addressed to: MS PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: September 10, 2007 Signature: Rosemarie Paljic-Salmeron
(Rosemarie Paljic-Salmeron)

Patent
Docket No. 229752004000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Benjamin P. WOOLVEN et al.

Serial No.: 11/659,009

International Filing Date: December 20, 2006

For: ANTI-INFLAMMATORY DAB

Examiner: Not Yet Assigned

Group Art Unit: 1632

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. Copies of U.S. Patent Application Nos. 11/636,338, 11/670,261; 11/830,713; 11/831,731; 11/831,751; 11/832,553 (documents nos. 108, 109, 110, 111, 112, and 113, respectively, on the attached Form PTO/SB/08a/b) are not included herewith. This protocol conforms with the waiver of the requirement under 37 C.F.R. § 1.98 to provide copies of pending U.S. Patent Applications. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

☐ With the application; accordingly, no fee or separate requirements are required.

☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.

☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.

- ☐ A fee is required. A check in the amount of __ is enclosed.
- ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is believed to be due.

☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.

- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of __ is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist;

(iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 229752004000.

Dated: September 10, 2007

Respectfully submitted,

By _____

Kimberly A. Bolin
Registration No.: 44,546
MORRISON & FOERSTER LLP
755 Page Mill Road
Palo Alto, California 94304-1018
(650) 813-5740

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	11/659,009
				Filing Date	(Int'l) December 20, 2006
				First Named Inventor	Benjamin P. WOOLVEN
				Art Unit	1632
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	1	of	5	Attorney Docket Number	229752004000

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-2003/0039649-A1	02-27-2003	Foote	
	2.	US-2003/0215427-A1	11-20-2003	Jensen	
	3.	US-2003/0232971-A1	12-18-2003	Rathjen et al.	
	4.	US-2005/0118643-A1	06-02-2005	Burgess et al.	
	5.	US-2005/0271663-A1	12-08-2005	Ignatovich et al.	
	6.	US-2006/0210526-A1	09-21-2006	Brocchini et al.	
	7.	US-4,002,531	01-11-1977	Royer	
	8.	US-4,816,567	03-28-1989	Cabilly et al.	
	9.	US-5,223,409-A	06-29-1993	Ladner et al.	
	10.	US-5,225,539-A	07-06-1993	Winter	
	11.	US-5,349,052-A	09-20-1994	Delgado et al.	
	12.	US-5,403,484-A	04-04-1995	Ladner et al.	
	13.	US-5,427,908-A	06-27-1995	Dower et al.	
	14.	US-5,571,698-A	11-05-1996	Ladner et al.	
	15.	US-5,580,717-A	12-03-1996	Dower et al.	
	16.	US-5,585,089-A	12-17-1996	Queen et al.	
	17.	US-5,612,460-A	03-18-1997	Zalipsky	
	18.	US-5,627,052-A	05-06-1997	Schrader	
	19.	US-5,837,500-A	11-17-1998	Ladner et al.	
	20.	US-5,885,793-A	03-23-1999	Griffiths et al.	
	21.	US-5,892,019-A	04-06-1999	Schlom et al.	
	22.	US-5,969,108-A	10-19-1999	McCafferty et al.	
	23.	US-5,977,307-A	11-02-1999	Friden et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	24.	EP-0 368 684-B2	05-16-1990	Medical Research Council et al.		
	25.	EP-0 436 597-B1	07-17-1991	Protein Engineering Corporation		
	26.	EP-0 527 839-B1	02-24-1993	Affymax Technologies N.V.		
	27.	EP-0 589 877-B2	04-06-1994	Cambridge Antibody Technology Limited et al.		
	28.	EP-0 605 442-B1	07-13-1994	IDEC Pharmaceuticals Corporation		
	29.	WO-89/01974-A1	03-09-1989	Celltech Limited		
	30.	WO-89/07142-A1	08-10-1989	Morrison		
	31.	WO-91/17271-A1	11-14-1991	Affymax Technologies N.V.		
	32.	WO-92/02551-A1	02-20-1992	B.R. Centre Limited et al.		
	33.	WO-92/09690-A2, A3	06-11-1992	Genentech, Inc.		
	34.	WO-92/20791-A1	11-26-1992	Cambridge Antibody Technology Limited et al.		
	35.	WO-95/06058-A1	03-02-1995	Royal Free Hospital School of Medicine		

Examiner Signature		Date Considered	

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	11/659,009
				Filing Date	(Int'l) December 20, 2006
				First Named Inventor	Benjamin P. WOOLVEN
				Art Unit	1632
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	2	of	5	Attorney Docket Number	229752004000

	36.	WO-97/08320-A1	03-06-1997	Morphosysgesellschaft Für Proteinoptimierung MBH		
	37.	WO-97/29131-A1	08-14-1997	BASF Aktiengesellschaft		
	38.	WO-98/31700-A1	07-23-1998	The General Hospital Corporation		
	39.	WO-98/32466-A1	07-30-1998	Polymascpharmaceuticals Plc		
	40.	WO-98/49286-A3	11-05-1998	Board of Regents, The University of Texas System		
	41.	WO-99/26711-A1	06-03-1999	McGoey et al.		
	42.	WO-99/36569-A1	07-22-1999	The Board of Trustees of the University of Illinois		
	43.	WO-00/40712-A1	07-13-2000	Medical Research Council		
	44.	WO-02/077029-A2, A3	10-03-2002	City of Hope		
	45.	WO-03/085089-A2, A3	10-16-2003	Schering Corporation et al.		
	46.	WO-2004/003019-A2, A3	01-08-2004	Domantis Limited		
	47.	WO-2004/081026-A2, A3	09-23-2004	Domantis Limited		
	48.	WO-2007/019620-A1	02-22-2007	Peptech Limited		
	49.	WO-2007/019621-A1	02-22-2007	Peptech Limited		
	50.	WO-2007/070948-A1	06-28-2007	Peptech Limited		
	51.	WO-2007/087673-A1	08-09-2007	Peptech Limited		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	52.	Babcook, J.S. et al. (July 1996). "A Novel Strategy for Generating Monoclonal Antibodies from Single, Isolated Lymphocytes Producing Antibodies of Defined Specificities," *Proc. Natl. Acad. Sci. USA* 93:7843-7848.	
	53.	Barbas III, C.F. et al. (September 1991). "Assembly of Combinatorial Antibody Libraries on Phage Surfaces: The Gene III Site," *Proc. Natl. Acad. Sci. USA* 88:7978-7982.	
	54.	Bird, R.E. et al. (October 21, 1988). "Single-Chain Antigen-Binding Proteins," *Science* 242:423-426.	
	55.	Chirino, A.J. (January 2004). "Minimizing the Immúnogenicity of Protein Therapeutics," *Drug Discovery Today* 9(2):82-90.	
	56.	Clackson, T. et al. (August 15, 1991). "Making Antibody Fragments Using Phage Display Libraries," *Nature* 352:624:628.	
	57.	Conrad, U. et al. (1998). "Compartment-Specific Accumulation of Recombinant Immunoglobulins in Plant cells: An Essential Tool for Antibody Production and Immunomodulation of Physiological Functions and Pathogen Activity," *Plant Molecular Biology* 38:101-109.	
	58.	Cramer, C.L. et al. (1999). "Transgenic Plants for Therapeutic Proteins: Linking Upstream and Downstream Strategies," Chapter 240 *In* Current Topics in Microbiology and Immunology, R.W. Compans et al. eds., Springer-Verlag: Berlin, pp. 95-118.	

Examiner Signature		Date Considered	

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	11/659,009
				Filing Date	(Int'l) December 20, 2006
				First Named Inventor	Benjamin P. WOOLVEN
				Art Unit	1632
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	3	of	5	Attorney Docket Number	229752004000

	59.	Delgado, C. et al. (1992). "The Uses and Properties of PEG-Linked Proteins," *Critical Reviews in Therapeutic Drug Carrier Systems* 9(3,4):249-304.	
	60.	Devereux, J. et al. (1984). "A Comprehensive Set of Sequence Analysis Programs for the VAX," *Nucleic Acids Research* 12(1):387-395.	
	61.	Ehrlich, P.H. et al. (1987). "Rhesis Monkey Responses to Multiple Injections of Human Monoclonal Antibodies," *Hybridoma* 6(2):151-160.	
	62.	Ehrlich, P.H. et al. (1988). "Human and Primate Monoclonal Antibodies for in Vivo Therapy," *Clinical Chemistry* 34(9):1681-1688.	
	63.	Fischer, R. et al. (1999). "Towards Molecular Farming in the Future: Moving from Diagnostic Protein and Antibody Production in Microbes to Plants," *Biotechnol. Appl. Biochem.* 30:101-108.	
	64.	Francis, G.E. et al. (1998). "PEGylation of Cytokines and Other Therapeutic Proteins and Peptides: The Importance of Biological Optimisation of Coupling Techniques," *International Journal of Hematology* 68:1-18.	
	65.	Fuchs, P. et al. (December 1991). "Targeting Recombinant Antibodies to the Surface of *Escherichia Coli*: Fusion to a Peptidoglycan Associated Lipoprotein," *Bio/Technology* 9:1369-1372.	
	66.	Garrard, L.J. et al. (December 1991). "F_{AB} Assembly and Enrichment in a Monovalent Phage Display System," *Bio/Technology* 9:1373:1377.	
	67.	GenBank Accession No. AAB37424, created December 13, 2006, located at http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&id=9665263, last visited on August 8, 2007, 3 pages.	
	68.	Gram, H. et al. (April 1992). "*In Vitro* Selection and Affinity Maturation of Antibodies from a Naive Combinatorial Immunoglobulin Library," *Proc. Natl. Acad. Sci. USA* 89:3576-3580.	
	69.	Griffiths, A.D. et al. (1993). "Human Anti-Self Antibodies with High Specificity from Phage Display Libraries," *The EMBO Journal* 12(2):725-734.	
	70.	Hammer, J. et al. (December 1994). "Precise Prediction of Major Histocompatibility Complex Class II-Peptide Interaction Based on Peptide Side Chain Scanning," *J. Exp. Med.* 180:2353-2358.	
	71.	Hawkins, R.E. et al. (1992). "Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation," *J. Mol. Biol.* 226:889-896.	
	72.	Hay, B.N. et al. (April 1992). "Bacteriophage Cloning and *Escherichia coli* Expression of a Human IgM Fab," *Hum. Antibod. Hybridomas* 3:81-85.	
	73.	Holliger, P. et al. (July 1993). "'Diabodies': Small Bivalent and Bispecific Antibody Fragments," *Proc. Natl. Acad. Sci. USA* 90:6444-6448.	
	74.	Holt, L.J. et al. (November 2003). "Domain Antibodies: Proteins for Therapy," *TRENDS in Biotechnology* 21(11):484-490.	
	75.	Hood, E.E. et al. (1999). "Molecular Farming of Industrial Proteins from Transgenic Maize," *Adv. Exp. Med. Biol.* 464:127-147.	
	76.	Hoogenboom, H.R. et al. (1991). "Multi-Subunit Proteins on the Surface of Filamentous Phage: Methodologies for Displaying Antibody (Fab) Heavy and Light Chains," *Nucleic Acids Research* 19(15):4133-4137.	
	77.	Huse, W.D. et al. (December 8, 1989). "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," *Science* 246:1275-1281.	
	78.	Huston, J.S. et al. (August 1988). "Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in *Escherichia Coli*," *Proc. Natl. Acad. Sci. USA* 85:5879-5883.	
	79.	International Search Report mailed on March 15, 2007, for PCT Application No. PCT/AU2006/001940 filed on December 20, 2007, three pages.	

Examiner Signature		Date Considered	

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	11/659,009
				Filing Date	(Int'l) December 20, 2006
				First Named Inventor	Benjamin P. WOOLVEN
				Art Unit	1632
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	4	of	5	Attorney Docket Number	229752004000

	80.	International Search Report mailed on March 16, 2007, for PCT Application No. PCT/AU2007/000085 filed on February 1, 2007, three pages.	
	81.	International Search Report mailed on October 30, 2006, for PCT Application No. PCT/AU2006/001165 filed on August 15, 2006, one page.	
	82.	International Search Report mailed on October 30, 2006, for PCT Application No. PCT/AU2006/001166 filed on August 15, 2006, one page.	
	83.	Irving, R.A. et al. (2001). "Ribosome Display and Affinity Maturation: From Antibodies to Single V-Domains and Steps Towards Cancer Therapeutics," *Journal of Immunological Methods* 248:31-45.	
	84.	Kabat E.A. et al. (1971). "Attempts to Locate Complementarity-Determining Residues in the Variable Positions of Light and Heavy Chains," *Annals New York Academy of Sciences* pp. 382-393.	
	85.	Kabat, E.A. et al. (1983). "Sequences of Proteins of Immunological Interest, Tabulation and Analysis of Amino Acid and Nucleic Acid Sequences of Precursors, V-Regions, C-Regions, J-Chain, β_2-Microglobulins, Major Histocompatibility Antigens, Thy-1, Complement, C-Reactive Protein, Thymopoietin, Post-Gamma Globulin, and α_2-Macroglobulin," *U.S. Department of Health and Human Services*, 349 pages.	
	86.	Keffer, J. et al. (1991). "Transgenic Mice Expressing Human Tumour Necrosis Factor: A Predictive Genetic Model of Arthritis," *The EMBO Journal* 10(13):4025-4031.	
	87.	Kipriyanov, S.M. et al. (1994). "Recombinant Single-Chain Fv Fragments Carrying C-Terminal Cysteine Residues: Production of Bivalent and Biotinylated Miniantibodies," *Mol. Immunol.* 31:1047-1058.	
	88.	Kipriyanov, S.M. et al. (1995). "Single-Chain Antibody Streptavidin Fusions: Tetrameric Bifunctional scFv-Complexes with Biotin Binding Activity and Enhanced Affinity to Antigen," *Hum. Antibod. Hybridomas* 6(3):93-101.	
	89.	Knappik, A. et al. (2000). "Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL) Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides," *J. Mol. Biol.* 296:57-86.	
	90.	Kong, Y-Y. et al. (January 28, 1999). "OPGL is a Key Regulator of Osteoclastogenesis, Lymphocyte Development and Lymph-Node Organogenesis," *Nature* 397:315-323.	
	91.	Kong, Y-Y. et al. (November 18, 1999). "Activated T Cells Regulate Bone Loss and Joint Destruction in Adjuvant Arthritis Through Osteoprotegerin Ligand," *Nature* 402:304-309.	
	92.	Kozlowski, A. et al. (2001). "Improvements in Protein PEGylation: Pegylated Interferons for Treatment of Hepatitis C," *Journal of Controlled Release* 72:217-224.	
	93.	Langermans, J.A.M. et al. (2000). "Reactivity of Human T-Lymphocyte-Specific Antibodies with Peripheral Blood Mononuclear Cells and Spleen of *Aotus azarae* ssp. *boliviensis* (Owl Monkey)," *J. Med. Primatol.* 29:397-401.	
	94.	Ma, J.K.-C. et al. (1995). "Plant Antibodies for Immunotherapy," *Plant Physiol.* 109:341-346.	
	95.	Ma, J.K.-C. et al. (December 1995). "Immunotherapeutic Potential of Antibodies Produced in Plants," *TIBTECH* 13, 6 pages.	
	96.	Matthews, N. et al. (1987). "Cytotoxicity Assays for Tumour Necrosis Factor and Lymphotoxin," Chapter 12 *In* Lymphokines and Interferons, a Practical Approach, Clemens, M.J. et al., eds., IRL Press, pp. 221-225.	
	97.	McCafferty, J. et al. (December 6, 1990). "Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains," *Nature* 348:552-554.	
	98.	Muñoz, E. et al. (1998). "The C_H1 Domain of IgG is Not Essential for C3 Covalent Binding: Importance of the Other Constant Domains as Targets for C3," *International Immunology* 10(2):97-106.	
	99.	Needleman, S.B. et al. (1970). "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins," *J. Mol. Biol.* 48:443-453.	

Examiner Signature		Date Considered	

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				**Complete if Known**	
				Application Number	11/659,009
				Filing Date	(Int'l) December 20, 2006
				First Named Inventor	Benjamin P. WOOLVEN
				Art Unit	1632
				Examiner Name	Not Yet Assigned
Sheet	5	of	5	Attorney Docket Number	229752004000

	100.	Oh, H. et al. (August 1999). "The Potential Angiogenic Role of Macrophages in the Formation of Choroidial Neovascular Membranes," *Investigative Ophthalmology & Visual Science* 40(9):1891-1898.	
	101.	Pankow, R. et al. (2000). "The HTLV-I Tax Protein Transcriptionally Modulates OX40 Antigen Expression," *The Journal of Immunology* 165:263-270.	
	102.	Poljak, R.J. et al. (December 15, 1994). "Production and Structure of Diabodies," *Structure* 2:1121-1123.	
	103.	Qin, W. et al. (2007). "A Novel Domain Antibody Rationally Designed Against TNF-α Using Variable Region of Human Heavy Chain Antibody as Scaffolds to Display Antagonistic Peptides," *Molecular Immunology* 44:2355-2361.	
	104.	Rajpal, A. et al. (June 14, 2005). "A General Method for Greatly Improving the Affinity of Antibodies by Using Combinatorial Libraries," *Proc. Natl. Acad. Sci. USA* 102(24):8466-8471.	
	105.	Roberts, R.W. et al. (November 1997). "RNA-Peptide Fusions for the *in vitro* Selection of Peptides and Proteins," *Proc. Natl. Acad. Sci. USA* 94:12297-12302.	
	106.	Scallon, B.J. et al. (April 1995). "Chimeric Anti-TNF-α Monoclonal Anti-Body cA2 Binds Recombinant Transmembrane TNF-α and Activates Immune Effector Functions," *Cytokine* 7(3):251-259.	
	107.	Stern, A.S. et al. (September 1990). "Purification to Homogeneity and Partial Characterization of Cytotoxic Lymphocyte Maturation Factor from Human B-Lymphoblastoid Cells," *Proc. Natl. Acad. Sci. USA* 87:6808-6812.	
	108.	United States Patent Application No. 11/636,338 filed on December 8, 2006, for Jennings et al.	
	109.	United States Patent Application No. 11/670,261 filed on February 1, 2007 for Doyle et al.	
	110.	United States Patent Application No. 11/830,713 filed on July 30, 2007, for Woolven et al.	
	111.	United States Patent Application No. 11/831,731 filed on July 31, 2007, for Doyle et al.	
	112.	United States Patent Application No. 11/831,751 filed on July 31, 2007, for Jennings et al.	
	113.	United States Patent Application No. 11/832,553 filed on August 1, 2007 for Jennings et al.	
	114.	van den Beucken, T. et al. (2001). "Building Novel Binding Ligands to B7.1 and B7.2 Based on Human Antibody Single Variable Light Chain Domains," *J. Mol. Biol.* 310:591-601.	
	115.	von Büdingen, H-C. et al. (2001). "Characterization of the Expressed Immunoglobulin IGHV Repertoire in the New World Marmoset *Callithrix jacchus*," *Immunogenetics* 53:557-563.	
	116.	Walter et al. (1996). "Sequences of the Human Germline V_H, V_K, J_H and J_K Segments," *In* Antibody Engineering: A Practical Approach, pp. 316-318.	
	117.	Ward, E.S. et al. (October 12, 1989). "Binding Activities of a Repertoire of Single Immunoglobulin Variable Domains Secreted from *Escherichia coli*," *Nature* 341:544-546.	
	118.	Whitelam, G.C. et al. (1994). "Antibody Production in Transgenic Plants," *Biochem. Soc. Trans.* 22:940-944.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	